Physician profile
Maria Arango
NPI 1053313809
$1,867.64
in general payments reported to CMS, 2019-2025
14 companies · $46.13 in 2025
The $46.13 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $27.12 · 2021: $232 · 2022: $444 · 2023: $744 · 2024: $116 · 2025: $46.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $892 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.76 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $435.97 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $340.87 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $260.90 | 2022-2024 | |
| Lilly USA, LLC | $186.63 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Astellas Pharma US INC | $127.22 | 2021-2023 | Veozah, Myrbetriq |
| Abbvie INC. | $98.42 | 2021-2023 | Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $84.13 | 2023-2025 | Rexulti |
| Amgen INC. | $83.82 | 2021-2023 | Otezla, Repatha, Prolia |
| Pfizer INC. | $56.47 | 2023 | |
| Genentech USA, INC. | $55.49 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.42 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $40.06 | 2022-2023 | |
| Amarin Pharma, INC. | $30.56 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Arango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.